Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,960 |
Reported balance
After 2026-01-30 transaction · row 1
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 53,960 · Balance 53,960 F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 53,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034628 · ownership.xml · nonDerivative · entry 1 Cusack Thomas · CIK 0002094824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,960 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| November 08, 2025 Filed Nov 12, 2025 14:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 227,272 | $1.10 Strike: $1.10 | $249,999.20 |
DisclosureSEC source: 0001193125-25-276244 · ownership.xml · derivative · entry 2 Cusack Thomas · CIK 0002094824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,272 Underlying: Common Stock · 227,272 shares Expires 2035-11-08 F3 · derivative.exercise_date: The stock options vest and become exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| November 08, 2025 Filed Nov 12, 2025 14:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 37,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-276244 · ownership.xml · nonDerivative · entry 1 Cusack Thomas · CIK 0002094824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,879 F1 · security: The shares were granted as restricted stock units which vest in 16 equal quarterly installments beginning one quarter after the date of grant. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.